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Introduction 
          Opioid prescribing and deaths in the United States have increased 
exponentially in the last several decades.   As of 2011, the American Academy of 
Pain Medicine and the Institute of Pain Medicine, estimate there are 100 million 
people with chronic pain.  This is more than cancer, diabetes and heart disease 
combined.  The CDC reports that in 2012 there were 41,502 deaths due to drug 
poisoning (often referred to as drug-overdose deaths) in the United States, of 
which 16,007 involved opioid analgesics.  
          In the zeal to treat pain as the fifth vital sign, we are now realizing that 
patients have not been appropriately treated for their pain.  Opiods have been a 
mainstay in the treatment of acute pain, cancer, and palliative care.  However, a 
recent paradigm shift over the last several years has seen a surge in treatment of 
chronic non-cancer pain with narcotics.  Chronic non-cancer pain (CNCP) causes 
significant morbidity, interfering with a patient’s ability to perform activities of 
daily living, family life, and employment and is associated with significant 
psychological stress. 
          While several states have already instituted a prescription drug monitoring 
program(PDMP), legislation passed on Jaunary 1, 2017 in the the states of 
Pennsylvania mandating physicians screen patients prior to prescribing narcotics 
and other Schedule II –V drugs.  This epidemic has left us posing a critical 
question—how can we screen patients and monitor their prescription habits.  
Objectives 
          With this newly instituted mandate, we found that many of the resident did 
not have access to the PDMP query site.  Our initial goal is to have 100% of 
residents have log-in access to the PDMP site.    Our long-term goals involve 
increasing the query of the PDMP website by OB-GYN residents prior to 
prescribing narcotic pain medication. 
          There are several changes that we can make to result in improvement of our 
initial goal including: identifying  residents that require access, working with 
program coordinator to identify gaps in their PDMP application, and assisting in 
providing DOH with any additional documentation necessary for access.   
          We will measure our improvement with a survey of residents as to their 
ability to access the PDMP website prior to our intervention and afterwards.  
After the intervention we wish to survey the residents on their use and utilization 






          From May 8-18, 2017, the obstetrics and gynecology residents at Thomas 
Jefferson University were surveyed on their views  and compliance of the 
Philadelphia Drug Monitoring Program.  Out of the 29 residents in the program, 
28 residents responded to the survey.  The survey consisted of 12 questions 
addressing a variety of views and compliance questions. Of the residents that 
responded to the survey, 29% have their own access to the database and every 
class has more than 50% of their class without access.  95% of residents have 
attempted to gain access without success.  Some statements that prevented 
completing the process included a cumbersome process, denial of registration,  
and the system “not working.”  More than 50% of residents never query the 
database when prescribing their narcotic, regardless of whether they have access 
or use another person’s login.  Of those residents that have access, 89% use the 
system to query patients.   Despite these statistics, 75% of residents feel that the 
database is a useful tool for preventing prescription abuse and 77% feel that 
querying the database changes their counseling of the patient.  100 % of residents 
indicated they would offer providing personal information in order to receive 
assistance in obtaining access. 
Conclusion 
Opioid pain medications remain a mainstay of CNCP treatment, but the 
number of overdoses or deaths due to these medications continues to climb. A 
multimodal approach must be utilized to address this crisis, including a more 
complete understanding of individual prescriber habits and the sources of 
patient’s narcotic prescriptions. Prescription drug monitoring programs aim to 
curtail these injuries by allowing prescribers to see individual patient’s narcotic 
history, altering their counseling or prescription choices based on the results of 
the system query. 
Our survey of OBGYN residents at a large, urban, academic hospital has 
demonstrated that utilization of the PDMP is severely limited by resident 
physician access to the PDMP. Interestingly, while residents predominantly 
agreed that PDMP queries were useful for preventing abuse, more than half of 
respondents indicated that they never query the database. Developing 
department-wide PDMP registration programs and further integration of the 
PDMP database into the existing EMR may increase utilization by increasing 
ease of access. 
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